Amongst all therapies, AXS-05 and Spravato are expected to have blockbuster potential and shall account for the highest revenue in the Major depressive disorder market over the coming years.
LAS VEGAS, Aug. 16, 2021 /PRNewswire/ — DelveInsight’s Major Depressive Disorder Market report offers detailed information on current treatment practices, emerging drugs, Major Depressive Disorder market share of the individual therapies, current and forecasted Major Depressive Disorder market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Some of the key highlights from the Major Depressive Disorder Market Report:
- As per DelveInsight’s estimate, the total Major Depressive Disorder prevalent cases in 2020 were reported to be 43,845,330 in the 7MM.
- The MDD therapy market space is currently monopolized by cheap and generic drugs, thus, impacting the overall market size.
- The Major Depressive Disorder therapeutic market size appears to be dominated by the United States in 2020, worth USD 2,333.2 million.
- Key pharmaceutical and biotech companies actively engaged in the Major Depressive Disorder market space include Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Biosciences, Relmada Therapeutics, Praxis Precision Medicines, among others.
- The Major Depressive Disorder pipeline therapies expected to get launched in the forecasted period (2021-2030) include Travivo (Fabre-Kramer Pharmaceuticals), Vraylar (Allergan/Gedeon Richter), PDC-1421 (Biolite Inc.), AV-101 (VistaGen Therapeutics), AXS-05 (Axsome Therapeutics), Pramipexole (Chase Therapeutics), SAGE-217 (Sage Therapeutics), LY03005 (Luye Pharma Group), Seltorexant (Minerva Therapeutics), PH10 (VistaGen Therapeutics), PRAX-114 (Praxis Precision Medicines), REL-1017 (Relmada Therapeutics), Caplyta (Intra-Cellular Therapies), and others. The expected launch of the pipeline therapies is expected to create a positive shift in the market during the forecast period (2021-2030).
- Out of the emerging therapies, the expected launch of AXS-05 and Spravato shall significantly boost the growth of the MDD market size during the forecast period. AXS-05 is a novel, oral NMDA receptor antagonist which has received breakthrough therapy designation from the USFDA.
- DelveInsight estimates that owing to better diagnosis, awareness, and treatment facilities available, and the USA is expected to account for the maximum Major Depressive Disorder market share in the forecasted period.
- The increase in the Major Depressive Disorder market size is attributed to extensive research and
development activities of pharmaceutical companies, launch of upcoming therapies, increasing MDD prevalence, and better awareness around the disorder.
- The rising prevalence of major depression and the emergence of novel pharmacotherapies, immediate depressive symptom relievers shall fundamentally alter the Major depressive disorder therapeutic landscape, thereby driving its growth.
Download Major Depressive Disorder Market Snapshot report to understand which Major Depressive Disorder drug is going to nab the maximum market share @ Major Depressive Disorder Therapy Market Analysis and Forecast
Major Depressive Disorder: Disease Overview
Major Depressive Disorder (MDD) is one of the most prevalent psychiatric disorders. The disorder is characterized by persistent sadness, loss of interest or pleasure, low energy, worse appetite and sleep, and even suicide, disrupting daily activities and psychosocial functions.
MDD is the leading cause of disease burden in high-income countries by 2030. Moreover, the estimates demonstrated that MDD affects more than 300 million people globally, and with a substantial increase reported over the last decade.
DelveInsight’s Major Depressive Disorder epidemiological analysis demonstrated that the United States accounted for the highest Major Depressive Disorder prevalence in the 7MM in 2020 while Spain accounted for the least MDD prevalent population. The trends can be attributed to the lowest overall population in Spain and the highest overall population in the United States among the 7MM.
DelveInsight’s Major Depressive Disorder Market Insights Report offers historical as well as forecasted epidemiological analysis during the study period 2018-30 in the 7MM segmented into:
- 12 Months Prevalent Cases of Major Depressive Disorder prevalent cases
- Gender-specific Major Depressive Disorder Prevalent Cases
- Severity-specific Major Depressive Disorder Prevalent Cases
- Relapsed/Refractory Major Depressive Disorder Cases
Understand how Major Depressive Disorder Epidemiological Trends are going to shape by 2030 in 7 Major Markets by downloading @ Major Depressive Disorder Epidemiology Market Report Summary
Present Major Depressive Disorder Therapeutic Market Outlook
The available first-line pharmacotherapy options include selective serotonin reuptake inhibitors (SSRIs) and selective serotonin-norepinephrine reuptake inhibitors (SNRIs) with Second-line pharmacotherapy options include monoamine oxidase inhibitors (MAOIs) and tricyclic antidepressants (TCAs). Concomitant medication with the use of other antidepressants or antipsychotics is common in treated patients.
The Major Depressive Disorder treatment market is segmented based on various phases like the acute phase, continuation phase, and maintenance phase of treatment; however, different types of depression require different treatments. Currently, most MDD patients are treated with pharmacotherapy, psychotherapy, or a combination of both.
To meet MDD therapeutic goals, several pharmaceutical and biotech companies such as Axsome Therapeutics, Luye Pharma, Sage Therapeutics, Chase Therapeutics, Minerva Biosciences, Relmada Therapeutics, Praxis Precision Medicines, and several others are committedly working to keep the market growth steady, displaying a promising future picture.
Difficulty in achieving remission
The criteria and definition of remission with treatment for MDD differ across the available guidelines. The APA practice guidelines and ACNP Taskforce indicate remission is achieved during the acute phase when patients experience at least 3 weeks without the core depressive symptoms of sad mood and reduced interest, and when patients present 3 or fewer symptoms meeting the criteria for an MDE. Whereas according to the DSM-5 manual, remission may be defined as a period of 2 or more months without symptoms or with 1 to 2 symptoms of MDD of mild severity. Patients who achieve partial remission present with a low number of residual symptoms from the previous MDE but no longer meet diagnostic criteria or experience a period of fewer than 2 months without any clinically significant depressive symptoms at the end of the index MDE. Full remission is characterized by a period of 2 months at the end of the index MDE without clinically depressed significant signs or symptoms.
Treatment-Resistant Depression (TRD)
TRD is a common clinical occurrence that affects a lot of patients with MDD. Patients who do not respond to treatment exhibit treatment-resistant symptoms and difficulties in social and occupational function, deterioration of physical health, suicidal ideation, and increased healthcare utilization. Currently, no clear consensus exists for TRD criteria, and more than 15 different definitions may exist; this inconsistency may interfere with research regarding TRD treatment options. However, an emerging consensus is that major depression is usually considered resistant when at least 2 appropriate trials of antidepressants from different pharmacological classes have failed to produce clinical remission.
There is not much improvement in the therapeutic options of MDD in the last three decades. Still, the expected entry of novel therapies with novel mechanisms of action by 2030 may change the treatment regimen of MDD and drive the market growth. AXS-05 and Spravato are expected to have blockbuster potential and shall create a huge positive shift in the market size of MDD during the forecast period (2021-2030).
Know which therapy is expected to score the touchdown first @ Major Depressive Disorder Therapeutic Pipeline and Market Forecast
- Travivo: Fabre-Kramer Pharmaceuticals
- Vraylar: Allergan/Gedeon Richter
- PDC-1421: Biolite Inc.
- AV-101: VistaGen Therapeutics
- AXS-05: Axsome Therapeutics
- Pramipexole (CTC-501): Chase Therapeutics
- SAGE-217: Sage Therapeutics
- LY03005: Luye Pharma Group
- Seltorexant: Minerva Therapeutics
- PH10: VistaGen Therapeutics
- PRAX-114: Praxis Precision Medicines
- REL-1017: Relmada Therapeutics
- Caplyta: Intra-Cellular Therapies
Learn more about available treatments @ Major Depressive Disorder Drug Pipeline Therapies
The Major Depressive Disorder size growth is anticipated to surge owing to an increasing awareness that shall lead to accurate diagnosis, therefore, timely treatment in primary care settings using antidepressant medications and/or brief structured psychological therapies. However, the growth is expected to be hindered by substantial barriers such as supply-side factors (for example, policies to invest resources, and consequent scarce mental health services, community and human resources), as well as demand-side issues (for example, lack of awareness of MDD as a treatable illness, and stigma and social exclusion associated with lower rates of help-seeking).
Nevertheless, the growing efforts to decrease the treatment gap for depression addressing both scaling up the supply of services and supporting people with depression and their family members to recognize that they have the condition and that it is treatable is going to bring about a boost in the MDD treatment market.
Discover more about the future market share of the therapies @ Major Depressive Disorder Treatment Market Landscape and Forecast
Scope of the Major Depressive Disorder Market Report
Coverage: 7MM (the US, EU5, and Japan)
Study Period: 2018-30
Key Companies: Fabre-Kramer Pharmaceuticals, Allergan/Gedeon Richter, Biolite IncVistaGen Therapeutics, Axsome Therapeutics, Chase Therapeutics, Sage Therapeutics, Luye Pharma Group, Minerva Therapeutics, VistaGen Therapeutics, Praxis Precision Medicines, Relmada Therapeutics, Intra-Cellular Therapies, and several others.
Key Major Depressive Disorder Pipeline Therapies: Travivo, Vraylar, PDC-1421, AV-101, AXS-05, Pramipexole, SAGE-217, LY03005, Seltorexant, PH10, PRAX-114, REL-1017, Caplyta, and several others.
Major Depressive Disorder Market Segmentation: By Geography, By Major Depressive Disorder Therapies
Analysis: Comparative and conjoint analysis of Major Depressive Disorder emerging therapies
Tools used: SWOT analysis, Conjoint Analysis, Porter’s Five Forces, PESTLE analysis, BCG Matrix analysis methods.
Drop by to learn more about the future market trends @ Major Depressive Disorder Market Landscape and Forecast
Table of Contents
Executive Summary of Major Depressive Disorder
Major Depressive Disorder Market Overview at a Glance
Competitive Intelligence Analysis for Major Depressive Disorder
Major Depressive Disorder Disease Background and Overview
Algorithm for Diagnosis of Major Depressive Disorder
Major Depressive Disorder Patient Journey
Major Depressive Disorder Epidemiology and Patient Population
Treatment Algorithm, Current Treatment, and Medical Practices
Major Depressive Disorder Epidemiology and Patient Population
Country Wise Epidemiology of Major Depressive Disorder
Access and Reimbursement Overview of Major Depressive Disorder
Key Endpoints of Major Depressive Disorder Treatment
Major Depressive Disorder Emerging Therapies
Major Depressive Disorder: 7 Major Market Analysis
Major Depressive Disorder Market Unmet Needs
Major Depressive Disorder Market Drivers
Major Depressive Disorder Market Barriers
Get in touch with our Business executive for Rich and Deep Market Assessment and Consulting Solutions
DelveInsight’s ‘Complex Regional Pain Syndrome (CRPS) – Market Insights, Epidemiology and Market Forecast—2030‘ report offers actionable insights into the CRPS market, epidemiology, pipeline therapies, and key companies including Ovid Therapeutics/Takeda, AstraZeneca/Biohaven Pharmaceutical, among others.
DelveInsight’s “Concussions Market Insights, Epidemiology, and Market Forecast-2030” report offers actionable insights into the Concussions market, epidemiology, pipeline therapies, and key companies including Sun Pharmaceutical, Sanofi, Oxeia Biopharmaceuticals, Astrocyte Pharmaceuticals, Tonix Pharmaceuticals Holding Corp., American CryoStem Corporation, Novartis/Amgen, Novo Nordisk A/S, Moleac Pte Ltd., Teva Pharmaceuticals, Stemedica, and others.
DelveInsight’s “Memory Disorders – Market Insights, Epidemiology, and Market Forecast-2030” report offers actionable insights into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Tianyin Pharmaceutical, Ipsen, Eisai, Merz Pharma, and others.
DelveInsight’s “Multiple Organ Dysfunction Syndrome Market Insights, Epidemiology, and Market Forecast-2030” report offers actionable insights into the Memory Disorder market, epidemiology, pipeline therapies, and key companies including Dart Neuroscience, Corcept Therapeutics, Cerecin, and others.
DelveInsight’s “Multiple Sclerosis Market Insights, Epidemiology, and Market Forecast-2030” report offers actionable insights into the Multiple Sclerosis market, epidemiology, pipeline therapies, and key companies including Biogen, NervGen, TG Therapeutics, Celgene Corporation, Brainstorm, MedDay Pharma, AB Science, Johnson & Johnson, Merck, among others.
DelveInsight’s “Narcotic Overdose – Market Insights, Epidemiology, and Market Forecast-2030” report.
DelveInsight’s ‘Narcolepsy–Market Insights, Epidemiology, and Market Forecast-2030‘ report offers actionable insights into the Narcolepsy market, epidemiology, pipeline therapies, and key companies including Cephalon Inc., Jazz Pharmaceuticals, among others.
DelveInsight’s ‘Bipolar Disorder (Manic Depression) – Market Insights, Epidemiology, and Market Forecast —2030′ report offers actionable insights into the Bipolar Disorder market, epidemiology, pipeline therapies, and key companies including Allergan (AbbVie)/Gedeon Richter, Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma), Intra-Cellular Therapies, NeuroRx, Sunovion (Sumitomo Dainippon Pharma), Lundbeck/Otsuka Pharmaceutical, Celon Pharma, COMPASS Pathways, among others.
DelveInsight’s ‘Postpartum Depression (PPD) – Market Insights, Epidemiology and Market Forecast – 2030’ report.
DelveInsight’s “Treatment resistant depression – Market Insights, Epidemiology, and Market Forecast-2030” report offers actionable insights into the TRD market, epidemiology, pipeline therapies, and key companies including Alkermes, Allergan/Gedeon Richter’s, ACADIA Pharmaceuticals, Axsome Therapeutics, Johnson and Johnson/Minerva Neurosciences, Celon Pharma, Relmada Therapeutics, VistaGen Therapeutics, Novartis, COMPASS Pathways, Allergan, VistaGen Therapeutics, among others.
Mental and addictive disorders affect a vast number of people, constituting more than 5% of all global burden of disease as measured in Disability Adjusted Life Years (DALYs).
The Bipolar depression pipeline includes Abilify, NRX-100/NRX101, Lumateperone, and Zuranolone, which are expected to grace the market in the next few years, thereby, presenting a promising Bipolar depression therapeutics market picture.
Discover more about different types of Mental health conditions and the therapeutics market landscape.
DelveInsight estimates an increasing trend of Schizophrenia prevalence in the 7MM, which was estimated to be 5,748,062 in 2020.
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. Discover how DelveInsight helped a Europe-based large-cap pharma company to assess its pipeline activities and make strategic decisions to outperform in the market through its Pharma and healthcare market competitive benchmarking services.